These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?The Motley Fool • 07/20/25
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.The Motley Fool • 07/19/25
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025PRNewsWire • 07/16/25
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition IntensifiesSeeking Alpha • 07/10/25
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In ObesityInvestors Business Daily • 06/25/25
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735PRNewsWire • 06/25/25
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street AnalystsThe Motley Fool • 06/21/25
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.The Motley Fool • 06/18/25
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?The Motley Fool • 06/16/25
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover PotentialSeeking Alpha • 06/02/25
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?Zacks Investment Research • 05/27/25